World-class expertise.
Leading-edge technologies.
Record-breaking success.
We’re taking medicine to new heights.
At Nimbus, exquisite selectivity is at the core of everything we do. From people to targets to molecules to partners, our meticulous choices enable us to successfully design and develop small molecule medicines capable of improving patients’ lives. And we have a track record to prove it.
Discover our unique approach to target selection, computational drug design, translational medicine, and clinical development.
Explore our highly selective small molecule medicines for oncology, immunology, and metabolic indications.
Nimbus Therapeutics Presents New Mechanistic Data Highlighting Differentiated Biology of Selective SIK2 Inhibitors at IMMUNOLOGY2026™
Nimbus Therapeutics to Present Preclinical and Translational Data on Novel SIK2 Inhibitors at 21st Congress of European Crohn’s and Colitis Organisation (ECCO)
